Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DANIELE MARIN

Allopathic & Osteopathic Physicians Radiology Diagnostic Radiology

NPI
1407152283
CMS profile
716637
Location
DURHAM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$56,650.36

51 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $37,750.00 36
Travel and Lodging $18,464.78 7
Food and Beverage $435.58 8

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $36,175.00 31
Siemens Medical Solutions USA, Inc. $18,900.36 15
Incyte Corporation $1,575.00 5

Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DANIELE MARIN

NPI 1407152283 · CMS profile ID 716637

Allopathic & Osteopathic Physicians / Radiology / Diagnostic Radiology

DURHAM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1407152283?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DANIELE MARIN, NPI 1407152283, CMS profile ID 716637. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1407152283?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). DANIELE MARIN, NPI 1407152283, CMS profile ID 716637. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1407152283?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
DANIELE MARIN, NPI 1407152283, CMS profile ID 716637, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1407152283?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

51 matching records · $56,650.36 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 51 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–51 of 51.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $2,690.0001/11/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131200966 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $21,849.30 44
PY2020 $194,788.50 42
PY2021 $283,309.29 46
PY2022 $16,238.30 7
PY2023 $39,296.42 23
PY2024 $56,650.36 51
PY2025 $61,836.72 38

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $104,084.76 39
PY2025 Principal investigator $430,375.00 19
PY2024 Recipient $21,378.98 15
PY2024 Principal investigator $570,249.94 42
PY2023 Recipient $9,720.00 15
PY2023 Principal investigator $1,147,318.00 22
PY2022 Recipient $38,910.00 22
PY2022 Principal investigator $141,147.50 40
PY2021 Recipient $106,016.68 22
PY2021 Principal investigator $159,253.14 31
PY2020 Recipient $73,989.83 24
PY2020 Principal investigator $140,881.64 12
PY2019 Recipient $33,274.00 10
PY2019 Principal investigator $95,225.28 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

58 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim Espana S.A. $35,160.00 12/19/2025 Non-covered Recipient Entity
GI Reviewers, LLC
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577698
Recipient Ipsen Innovation $416.00 12/04/2025 Covered Recipient Physician A Phase II, Randomized, Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics (PK) of Maintenance Cabozantinib (XL184) Plus Best Supportive Care (BSC) Versus BSC in Children, Adolescents and Young Adults (AYA) With Unresectable Residual Osteosarcoma Either at Diagnosis or at First Relapse After Standard Treatment No dispute reported 06/30/2026 1184302787
Principal investigator 1 Boehringer Ingelheim Espana S.A. $9,500.00 11/14/2025 Non-covered Recipient Entity
GI Reviewers, LLC
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577696
Recipient Ipsen Innovation $208.00 11/06/2025 Covered Recipient Physician A Phase II, Randomized, Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics (PK) of Maintenance Cabozantinib (XL184) Plus Best Supportive Care (BSC) Versus BSC in Children, Adolescents and Young Adults (AYA) With Unresectable Residual Osteosarcoma Either at Diagnosis or at First Relapse After Standard Treatment No dispute reported 06/30/2026 1184302785
Recipient GlaxoSmithKline, LLC. $5,724.09 10/15/2025 Covered Recipient Physician A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY WITH DOSTARLIMAB MONOTHERAPY I No dispute reported 06/30/2026 1192107424
Recipient GlaxoSmithKline, LLC. $4,252.13 10/15/2025 Covered Recipient Physician A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192107485
Principal investigator 1 Boehringer Ingelheim Espana S.A. $2,440.00 10/09/2025 Non-covered Recipient Entity
GI Reviewers, LLC
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577692
Principal investigator 1 Boehringer Ingelheim Espana S.A. $1,455.00 10/03/2025 Non-covered Recipient Entity
GI Reviewers, LLC
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577694
Recipient GlaxoSmithKline, LLC. $2,684.68 09/16/2025 Covered Recipient Physician A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192109893
Recipient GlaxoSmithKline, LLC. $2,684.68 09/16/2025 Covered Recipient Physician A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192109898
Recipient GlaxoSmithKline, LLC. $2,550.91 09/16/2025 Covered Recipient Physician A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY WITH DOSTARLIMAB MONOTHERAPY I No dispute reported 06/30/2026 1192109911
Principal investigator 1 Gilead Sciences, Inc. $5,340.00 08/26/2025 Non-covered Recipient Entity
RADMD LLC
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy No dispute reported 06/30/2026 1229212319
Recipient GlaxoSmithKline, LLC. $1,712.73 08/10/2025 Covered Recipient Physician A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY WITH DOSTARLIMAB MONOTHERAPY I No dispute reported 06/30/2026 1192107435
Recipient GlaxoSmithKline, LLC. $2,401.20 08/10/2025 Covered Recipient Physician A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192109887
Recipient GlaxoSmithKline, LLC. $2,501.25 07/15/2025 Covered Recipient Physician A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192107402
Recipient GlaxoSmithKline, LLC. $1,371.36 07/15/2025 Covered Recipient Physician A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY WITH DOSTARLIMAB MONOTHERAPY I No dispute reported 06/30/2026 1192107464
Principal investigator 1 Gilead Sciences, Inc. $10,020.00 07/10/2025 Non-covered Recipient Entity
RADMD LLC
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy No dispute reported 06/30/2026 1229212327
Principal investigator 1 Boehringer Ingelheim Espana S.A. $36,895.00 07/08/2025 Non-covered Recipient Entity
GI Reviewers, LLC
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577690
Recipient Regeneron Pharmaceuticals, Inc. $60.00 07/02/2025 Covered Recipient Physician A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184120047
Principal investigator 1 Amgen Inc. $1,225.00 06/19/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda (Pembrolizumab) in Subjects With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1246641846
Principal investigator 1 Boehringer Ingelheim Espana S.A. $22,625.00 06/19/2025 Non-covered Recipient Entity
GI Reviewers, LLC
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577688
Principal investigator 1 Gilead Sciences, Inc. $28,860.00 06/19/2025 Non-covered Recipient Entity
RADMD LLC
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy No dispute reported 06/30/2026 1229212336
Recipient GlaxoSmithKline, LLC. $3,890.00 06/19/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192107383
Recipient GlaxoSmithKline, LLC. $2,238.48 06/11/2025 Covered Recipient Physician A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192107068
Recipient GlaxoSmithKline, LLC. $1,114.54 06/11/2025 Covered Recipient Physician A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY WITH DOSTARLIMAB MONOTHERAPY I No dispute reported 06/30/2026 1192107410
Recipient GlaxoSmithKline, LLC. $562.50 06/11/2025 Covered Recipient Physician A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P No dispute reported 06/30/2026 1192107480
Principal investigator 1 Gilead Sciences, Inc. $13,440.00 06/05/2025 Non-covered Recipient Entity
RADMD LLC
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy No dispute reported 06/30/2026 1229212347
Principal investigator 1 Boehringer Ingelheim Espana S.A. $6,215.00 05/15/2025 Non-covered Recipient Entity
GI Reviewers, LLC
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577686
Recipient GlaxoSmithKline, LLC. $1,667.50 05/13/2025 Covered Recipient Physician A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192107074
Recipient GlaxoSmithKline, LLC. $3,262.50 05/13/2025 Covered Recipient Physician A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P No dispute reported 06/30/2026 1192107364
Recipient GlaxoSmithKline, LLC. $2,092.27 05/13/2025 Covered Recipient Physician A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY WITH DOSTARLIMAB MONOTHERAPY I No dispute reported 06/30/2026 1192107417
Principal investigator 1 Amgen Inc. $26,342.50 05/12/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO (Nivolumab) in Subjects With Treatment-Nave Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 1246641825
Recipient Regeneron Pharmaceuticals, Inc. $900.00 05/08/2025 Covered Recipient Physician A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184120045
Recipient GlaxoSmithKline, LLC. $2,405.29 04/15/2025 Covered Recipient Physician A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY WITH DOSTARLIMAB MONOTHERAPY I No dispute reported 06/30/2026 1192107396
Recipient GlaxoSmithKline, LLC. $2,934.80 04/15/2025 Covered Recipient Physician A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192107468
Recipient GlaxoSmithKline, LLC. $7,441.00 04/15/2025 Covered Recipient Physician A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P No dispute reported 06/30/2026 1192109920
Principal investigator 1 Boehringer Ingelheim Espana S.A. $3,780.00 04/10/2025 Non-covered Recipient Entity
GI Reviewers, LLC
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577684
Principal investigator 1 Gilead Sciences, Inc. $1,000.00 04/10/2025 Non-covered Recipient Entity
RADMD LLC
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy No dispute reported 06/30/2026 1229212361
Recipient Regeneron Pharmaceuticals, Inc. $175.00 04/10/2025 Covered Recipient Physician A GLOBAL, RANDOMISED, PHASE 3, OPEN-LABEL STUDY OF REGN2810 (ANTI-PD 1 ANTIBODY) VERSUS PLATINUM BASED CHEMOTHERAPY IN FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC PD L1+NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184120041
Recipient Regeneron Pharmaceuticals, Inc. $700.00 04/10/2025 Covered Recipient Physician A GLOBAL, RANDOMISED, PHASE 3, OPEN-LABEL STUDY OF REGN2810 (ANTI-PD 1 ANTIBODY) VERSUS PLATINUM BASED CHEMOTHERAPY IN FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC PD L1+NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184120043
Principal investigator 1 Boehringer Ingelheim Espana S.A. $43,480.00 04/03/2025 Non-covered Recipient Entity
GI Reviewers, LLC
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577680
Principal investigator 1 Boehringer Ingelheim Espana S.A. $2,325.00 04/03/2025 Non-covered Recipient Entity
GI Reviewers, LLC
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577682
Recipient Regeneron Pharmaceuticals, Inc. $960.00 04/01/2025 Covered Recipient Physician A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184120037
Recipient Regeneron Pharmaceuticals, Inc. $1,320.00 04/01/2025 Covered Recipient Physician A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184120039
Recipient GlaxoSmithKline, LLC. $1,344.55 03/15/2025 Covered Recipient Physician A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY WITH DOSTARLIMAB MONOTHERAPY I No dispute reported 06/30/2026 1192107390
Recipient GlaxoSmithKline, LLC. $15,149.50 03/13/2025 Covered Recipient Physician A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P No dispute reported 06/30/2026 1192107378
Recipient GlaxoSmithKline, LLC. $761.25 03/13/2025 Covered Recipient Physician A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192107474
Recipient GlaxoSmithKline, LLC. $362.50 02/12/2025 Covered Recipient Physician A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192107372
Recipient GlaxoSmithKline, LLC. $8,552.63 02/12/2025 Covered Recipient Physician A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P No dispute reported 06/30/2026 1192109905
Recipient GlaxoSmithKline, LLC. $1,530.00 02/11/2025 Covered Recipient Physician A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY WITH DOSTARLIMAB MONOTHERAPY I No dispute reported 06/30/2026 1192107062
Recipient Ipsen Innovation $75.00 02/06/2025 Covered Recipient Physician A Phase II, Randomized, Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics (PK) of Maintenance Cabozantinib (XL184) Plus Best Supportive Care (BSC) Versus BSC in Children, Adolescents and Young Adults (AYA) With Unresectable Residual Osteosarcoma Either at Diagnosis or at First Relapse After Standard Treatment No dispute reported 06/30/2026 1184302783
Recipient Regeneron Pharmaceuticals, Inc. $420.00 02/06/2025 Covered Recipient Physician A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184120035
Recipient Regeneron Pharmaceuticals, Inc. $720.00 01/21/2025 Covered Recipient Physician A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184120033
Recipient GlaxoSmithKline, LLC. $1,083.87 01/15/2025 Covered Recipient Physician A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192107429
Recipient GlaxoSmithKline, LLC. $14,850.00 01/15/2025 Covered Recipient Physician A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P No dispute reported 06/30/2026 1192107441
Recipient GlaxoSmithKline, LLC. $1,004.55 01/15/2025 Covered Recipient Physician A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY WITH DOSTARLIMAB MONOTHERAPY I No dispute reported 06/30/2026 1192109880
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $176,772.50 01/14/2025 Non-covered Recipient Entity
GI Reviewers
Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy No dispute reported 06/30/2026 1235997097
Principal investigator 1 Boehringer Ingelheim Espana S.A. $3,500.00 01/09/2025 Non-covered Recipient Entity
GI Reviewers, LLC
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577678